Business, energy, technology, markets and global industry news from Business News Today

Precision BioSciences

PharmaDeviceNews Precision BioSciences
Precision BioSciences’ leadership reshuffle puts PBGENE-HBV and PBGENE-DMD clinical execution in focus as the gene-editing company approaches key 2026 milestones. Representative image.
Pharma & Biotech

Precision BioSciences prepares leadership team for PBGENE-HBV and PBGENE-DMD data milestones

Precision BioSciences reshapes leadership to support PBGENE-HBV and PBGENE-DMD as two gene-editing trials approach key 2026 milestones.

Read More
Pharma & Biotech

Russell 2000 inclusion puts Precision BioSciences before more investors at a pivotal clinical stage

See how Russell 2000 inclusion expands Precision BioSciences’ investor reach while PBGENE-HBV and PBGENE-DMD face critical clinical tests.

Read More
Representative image of neonatal gene therapy research in a modern clinical setting. iECURE’s ECUR-506 data have sharpened interest in whether targeted gene insertion could reduce hyperammonemic events in infants with neonatal-onset OTC deficiency.
Pharma & Biotech

Is iECURE’s infant gene editing therapy quietly changing the OTC deficiency playbook?

A rare disease gene editing signal is only the start. iECURE now has to prove ECUR-506 can sustain OTC deficiency control.

Read More